FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+advanced gastric/gastroesophageal junction adenocarcinoma (GC).

Affiliation auteurs!!!! Error affiliation !!!!
TitreFIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+advanced gastric/gastroesophageal junction adenocarcinoma (GC).
Type de publicationJournal Article
Year of Publication2021
AuteursCatenacci DVT, Kang Y-K, Saeed A, Yamaguchi K, Qin S, Lee K-W, Kim I-H, Oh SCheul, Li J, Turk HM, Teixeira ACarolina, Borg C, Hitre E, Udrea AAdrian, Cardellino GGerardo, Guardeno R, Mitra S, Yang Y, Enzinger PC, Wainberg ZA
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume39
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2021.39.15_suppl.4010